Genmab — Oktober 2014
-
sydbank har generelt været sælgere meget længe
-
Fra NICE: Pomalidomide, in combination with dexamethasone, is not
recommended within its marketing authorisation for treating
relapsed and refractory multiple myeloma in adults who have had at
least 2 prior treatments, including lenalidomide and bortezomib, and
whose disease has progressed on the last therapy. -
-
NICE er bare mega kritiske, de skal have kæmpe datamateriale at forholde sig til.
-
Jan der er godt nok stille fra genmab. 3 uger ca. til Q3 rapporten dog
-
Og anonyme tager fra igen idag
-
jo... men omvendt får vi en god nyhed på en dag som idag giver det jo næsten ingenting fordi ingen vil eje aktier pt.
-
Også derfor jeg ikke tror at en Darafiling vil give +10-15% når nyheden kommer. Tror mere på 5-10% og så vil den stige efterfølgende når analytikerne begynder at indprise den. Jeg tror ihvertfald sagtens man kan samle op efter nyheden. man behøver ikke positionere sig agressivt inden
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind